SLT Holdings’s BioXcel Therapeutics BTAI Stock Holding History

SLT Holdings’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-29,500	Closed	-$75.5K	–	146
2025 Q3	$75.5K	Buy	+29,500	New	+$93K	0.05%	136

Other funds holding BTAI

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OCM

Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SLT Holdings's BTAI Position: Q4 2025 in Review

SLT Holdings sold out of BioXcel Therapeutics (BTAI) in Q4 2025, closing a stake of 29,500 shares — an estimated $75.5K sold.

SLT Holdings first reported a position in BTAI in Q3 2025 and held it in 1 quarter. The position peaked at $75.5K in Q3 2025. 41 funds tracked by Wall St. Rank hold BTAI as of Q4 2025.

SLT Holdings reported no remaining BioXcel Therapeutics position as of Q4 2025 after selling out during the quarter.
SLT Holdings sold 29,500 BioXcel Therapeutics shares in Q4 2025, an estimated $75.5K.
SLT Holdings first reported a position in BioXcel Therapeutics in Q3 2025 and held it in 1 quarter.
SLT Holdings's BioXcel Therapeutics position peaked at $75.5K in Q3 2025.
41 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q4 2025.

Based on SLT Holdings's 13F filing for Q4 2025, filed 9 Feb 2026.